CONTINUING STUDIES Sample Clauses

CONTINUING STUDIES. 24.1 The parties agree that a market-driven Continuing Studies program has a valuable role to play in supporting and complementing the regular offerings of Langara College. Such an operation requires flexibility with respect to tuition fees; curriculum structure; methods, scheduling, cost and location of instruction; and other such matters. 24.2 For the purpose of this article, the term “Continuing Studies” shall mean all offerings of the College other than Regular Studies offerings as listed in the Langara College Calendar or its supplements and available through the Langara College Registration Guide and Course Schedule.
View SourceView Similar (12)
CONTINUING STUDIES. Continuing studies courses which are non-credit and non-transferable are not bargaining unit work.
View SourceView Similar (7)
CONTINUING STUDIES. If you are continuing to study externally during the coming year, please complete the following: I will be continuing to study for [ ] at [ ] We have agreed that [ ] hours each week will be set aside for studying – this will normally be on a [ ].
View SourceView Similar (4)
CONTINUING STUDIES. 24.1 The parties agree that a market-driven Continuing Studies program may have a valuable role to play in supporting and complementing the regular offerings of Langara College. Such an operation requires flexibility with respect to tuition fees; curriculum structure; methods, scheduling, cost and location of instruction; and other such matters. 24.2 The faculty of Langara College shall have a major role through their departments in determining educational standards and transferability for Continuing Studies offerings in the subject area(s) of the department. 24.3 This Collective Agreement does not apply to any employee engaged in Continuing Studies unless expressly stated in this article. 24.4 Where a course, or series of courses, offered by Continuing Studies has satisfied the following criteria: a) substantially similar content and similar degree of rigour in measuring student learning or b) transferability to past or present Langara College or BCCAT courses or programs, such course(s) shall be instructed by faculty members under the provision of this Collective Agreement. 24.5 The College agrees that the number of sections taught by faculty members in a subject area will not be reduced due to the offerings of Continuing Studies in that subject area. 24.6 Where Langara College identifies new Continuing Studies programs or courses to be developed for offering, faculty members will be notified of an opportunity to submit proposals two (2) weeks prior to the College seeking external proposals. 24.7 Langara Continuing Studies courses and sections not covered by Article 24.4 will be offered first to qualified faculty members except in the following cases: 24.7.1 Where a person or faculty member develops a course without compensation, Article 24.7 shall be waived in the event he/she also instructs the course. 24.7.2 A course identified in the 1995-96 VCC/Langara CE brochures which is offered before December 31, 1996 and which is transferred from VCC CE to Langara Continuing Studies, shall be exempted from the provision of 24.7 as long as the incumbent continues to instruct. 24.7.3 Effective January 1, 1997, Article 24.7 shall be waived as long as the incumbent continues to instruct. 24.8 Where faculty members instruct Continuing Studies courses other than those satisfying the criteria in 24.4, they shall do so at Continuing Studies rates of pay. 24.9 The parties agree to the establishment of an Advisory Committee on Continuing Studies (ACCS) in accordance wit...
View SourceView Similar (3)
CONTINUING STUDIES. April 1, 2004 – March 31, 2006 24.1 The parties agree that a market-driven Continuing Studies program may have a valuable role to play in supporting and complementing the regular offerings of Langara College. Such an operation requires flexibility with respect to tuition fees; curriculum structure; methods, scheduling, cost and location of instruction; and other such matters. 24.2 The faculty of Langara College shall have a major role through their departments in determining educational standards and transferability for Continuing Studies offerings in the subject area(s) of the department. 24.3 This Collective Agreement does not apply to any employee engaged in Continuing Studies unless expressly stated in this article. 24.4 Where a course, or series of courses, offered by Continuing Studies has satisfied the following criteria: a) substantially similar content and similar degree of rigour in measuring student learning or b) transferability to past or present Langara College or BCCAT courses or programs, such course(s) shall be instructed by faculty members under the provision of this Collective Agreement. 24.5 The College agrees that the number of sections taught by faculty members in a subject area will not be reduced due to the offerings of Continuing Studies in that subject area. 24.6 Where Langara College identifies new Continuing Studies programs or courses to be developed for offering, faculty members will be notified of an opportunity to submit proposals two (2) weeks prior to the College seeking external proposals. 24.7 Langara Continuing Studies courses and sections not covered by Article
View Source
CONTINUING STUDIES. 24.1 The parties agree that a market-driven Continuing Studies program may have a valuable role to play in supporting and complementing the regular offerings of Langara College. Such an operation requires flexibility with respect to tuition fees; curriculum structure; methods, scheduling, cost and location of instruction; and other such matters. 24.2 The faculty of Langara College shall have a major role through their departments in determining educational standards and transferability for Continuing Studies offerings in the subject area(s) of the department. 24.3 This Collective Agreement does not apply to any employee engaged in Continuing Studies unless expressly stated in this article. 24.4 Where a course, or series of courses, offered by Continuing Studies has satisfied the following criteria: a) substantially similar content and similar degree of rigour in measuring student learning or b) transferability to past or present Langara College or BCCAT courses or programs, such course(s) shall be instructed by faculty members under the provision of this Collective Agreement. 24.5 The College agrees that the number of sections taught by faculty members in a subject area will not be reduced due to the offerings of Continuing Studies in that subject area.
View Source

Related to CONTINUING STUDIES

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Development Plans As soon as practicable after formation of the JDC, the JDC shall prepare and approve the initial Development Plan for Development of the Licensed Product for the Initial Indication in the formulation existing as of the Effective Date in the Territory. The Parties shall use Commercially Reasonable Efforts to ensure that such initial Development Plan is consistent with the general Development Plan outline set forth in Exhibit B attached hereto and incorporated herein (the “General Development Plan Outline”). The JDC shall prepare and approve a separate Development Plan for Development of Licensed Product for the Initial Indication in the Initial Formulation in the Territory and for Development of each Other Indication Product and New Formulation (if any) in the Territory, and shall update and amend each Development Plan not less than annually or more frequently as needed to take into account changed circumstances or completion, commencement or cessation of Development activities not contemplated by the then-current Development Plan. Amendments and revisions to the Development Plan shall be reviewed and discussed, in advance, by the JDC, and Otsuka agrees to consider proposals and suggestions made by Acucela regarding amendments and revisions to the Development Plan. Any amendment or revision to the Development Plan that provides for an increase or decrease in the number of FTEs as compared to the previous version of the Development Plan, or that provides for addition or discontinuation of tasks or activities as compared to the previous version of the Development Plan, or that moves forward the timetable for activities reflected in the Development Plan, shall provide for a reasonable ramp-up or wind-down period, as applicable, to accommodate a smooth and orderly transition of Development activities to the amended or revised Development Plan. Each Development Plan shall identify the goals of the Development program contemplated thereunder and shall address Development activities related to the Licensed Compound or the Licensed Product (including, if applicable, any Other Indication Product or New Formulation), including: (i) the budget for Development Costs (and costs of Phase 4 Clinical Trials, if any) for the forthcoming calendar year (or portion thereof), including a reasonably detailed allocation of such costs and expenses among the activities expected to be conducted, including the number of FTEs (subject to Section 4.2) and the applicable FTE Rate and out-of-pocket expenses to be incurred in such calendar year (or portion thereof), and a reasonable good faith projection of the budget for Development Costs (and costs of Phase 4 Clinical Trials, if any) for Development activities in the Development Plan after such calendar year, in each case which budget shall be an amount reasonably intended to be sufficient to cover the anticipated costs associated with the activities reflected in the Development Plan; (ii) clinical trials (including Phase 4 Clinical Trials but excluding Phase 3b Clinical Trials or Post-Approval Studies) to generate data for use in seeking, obtaining or maintaining Regulatory Approval and for labeling of the Licensed Product for the Initial Indication in the Initial Formulation or, if applicable, Other Indication Product or New Formulation, including study protocol design; (iii) resources required to perform each required Development activity, including the scope of the work to be performed by internal resources of each of the Parties or by CROs or other permitted subcontractors, if applicable; (iv) milestones to be met, deliverables to be provided and the timeline for completion of each Development activity; (v) the members of the Development team, which must include at least one individual who has sufficient expertise and experience in ophthalmology drug development in the Initial Indication; (vi) design and implementation of regulatory strategy; and (vii) forecasts of quantities of Licensed Product to be supplied by Otsuka for use in clinical trials in the Territory.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Project Plans The Contractor: must carry out the Contractor's Activities in accordance with, and otherwise implement, the Project Plans; and for the purposes of subparagraph (i), must: prepare Project Plans based, where applicable, on the draft Project Plans lodged by the Contractor in its tender for the Contractor's Activities, and otherwise in accordance with the requirements of the Contract and submit them to the Contract Administrator so as to ensure that there is no delay or disruption to the Contractor's Activities and in any event no later than the number of days specified in the Contract Particulars after the Award Date for each Project Plan; not commence any of the Contractor's Activities to which any Project Plan applies, unless the Contract Administrator has had the number of days specified in the Contract Particulars for each Project Plan to review the Project Plan and has not rejected the Project Plan; if any Project Plan is rejected, submit an amended Project Plan to the Contract Administrator; in any event, finalise each Project Plan so as to ensure that there is no delay or disruption to the Contractor's Activities and in any event in accordance with the requirements of the Contract to the satisfaction of the Contract Administrator; after each Project Plan has been finalised: regularly review, update and amend each Project Plan in accordance with the process set out in each Project Plan (and otherwise at least on each anniversary of the Award Date); update or amend a Project Plan on request of the Contract Administrator; and continue to correct any defects in or omissions from a Project Plan (whether identified by the Contract Administrator or the Contractor), and submit an updated or amended Project Plan to the Contract Administrator, after which: the Contractor must continue to comply with the requirements of the then current Project Plan until the process in subparagraph (ii) has been completed in respect of the updated or amended Project Plan; and subsubparagraphs B - E will apply (to the extent applicable); and document and maintain detailed records of all: reviews, updates, amendments and submissions of each Project Plan; audits or other monitoring of each Project Plan; and training and awareness programs and communications provided to Contractor and subcontractor personnel in respect of each Project Plan (including each updated or amended Project Plan). The Contractor will not be relieved from compliance with any of its obligations under the Contract or otherwise at law or in equity as a result of: the implementation of, and compliance with, the requirements of any Project Plan; any direction by the Contract Administrator concerning a Project Plan or the Contractor's compliance or non-compliance with a Project Plan; any audit or other monitoring by the Contract Administrator or anyone else acting on behalf of the Commonwealth of the Contractor's compliance with a Project Plan; or any failure by the Contract Administrator, or anyone else acting on behalf of the Commonwealth, to detect any defect in or omission from a Project Plan including where any such failure arises from any negligence on the part of the Contract Administrator or other person.